On September 6, 2023 Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, reported two company presentations at investor conferences in September and October (Press release, Alentis Therapeutics, SEP 6, 2023, View Source [SID1234634933]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UBS Biotechnology Private Company Virtual Symposium
The virtual conference is to be held September 20-21, 2023. Roberto Iacone, Chief Executive Officer of Alentis will participate in a fireside chat on Thursday, September 21 at 8:30 am ET.

Oppenheimer Private Healthcare Company Showcase
The conference is to be held October 11, 2023 at The Intercontinental New York Barclay Hotel. Roberto Iacone will give a company presentation at 9:00 am ET in Track 1.